David Krasne

Chief Financial Officer at Nanocan Therapeutics Corporation

David Krasne has a diverse work experience spanning various leadership roles and industries. David co-founded RedNest Partners in 2016, where they currently serve as a Co-Founder and Partner. In 2012, they co-founded Sentire Medical Systems and ExpertConnect, where they held the positions of Director and Co-Founder, respectively. From 2010 to 2016, they served as the CEO and Director of American Medical Forensic Specialists. David is currently the Chief Financial Officer at Nanocan Therapeutics Corporation, a role they assumed in 2022. Additionally, they worked as a Director at Tecmotiv starting in 2019. Earlier in their career, they held positions such as Vice President at The Riverside Company and Chief Operating Officer at Professional Sports Publications. Prior to that, they served as a Principal at Merrill Lynch Global Private Equity, where they managed investments, executed transactions, and served on boards of directors. David started their career as an Investment Banking Analyst at Merrill Lynch & Co., focusing on valuation and merger and acquisition analyses in the Financial Institutions Group.

David Krasne's education history includes a Bachelor of Science degree in Finance and Accounting from Penn State University. David also pursued further education at the UCLA Anderson School of Management, where they obtained their MBA degree.

Location

New York, United States

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Nanocan Therapeutics Corporation

Nanocan Therapeutics provides medicines and other products intended to patients with certain cancers, respiratory tract infections. The company leverages nanotechnology to create solutions for hard-to-cure indications where current interventions are insufficient. Through the application of nanotechnology to medicine, Nanocan aims to help improvethe quality of life of our patients, increase access to medicine and other treatments, and to reduce global health disparities.


Employees

1-10

Links